Showing 1061-1070 of 1148 results for "".
- Metabolic Regulator Shows Promise for Life-Saving Treatment of Thymidine Kinase Deficiency Disordershttps://practicalneurology.com/news/metabolic-regulator-shows-promise-for-life-saving-treatment-of-thymidine-kinase-deficiency-disorders/2469047/In a global phase 2 study of pyrimidine nucleoside substrate enhancement therapy (SET) (MT1621; Modis Therapeutics/Zogenix, Oakland, CA) for treating thymidine kinase 2 (TK2) deficiency all treated participants survived. Most individuals treated with SET had improved (68%) or stabilized (26%) mot
- Sensory Deficits Increase Risk of Dementia for Older Adultshttps://practicalneurology.com/news/sensory-deficits-increase-risk-of-dementia-for-older-adults/2468956/New research suggests that sensory deficits may be associated with an increased risk of developing both all-cause dementia and Alzheimer’s disease (AD) dementia. In a study from the University of Washington School of Public Health, 2,827 individuals, age 75 or more, who had
- Many Patients Who Start Botulinum Toxin for Migraines Discontinue Treatment Earlyhttps://practicalneurology.com/news/many-patients-who-start-botulinum-toxin-for-migraines-discontinue-treatment-early/2468791/A real-world study revealed that less than half of patients who begin treatment with onabotulinumtoxinA (Botox; Allergan, Madison, NJ) to prevent chronic migraine receive all recommended treatments of the therapy. The study, being presented at the Academy of Managed Care Pharmacy's (AMCP) Man
- Real-World Use of Wrist-worn Neuromodulation Treatment of Essential Tremorshttps://practicalneurology.com/news/real-world-use-of-wrist-worn-neuromodulation-treatment-of-essential-tremors/2469435/A wrist-worn neuromodulation device (Cala Trio; Cala Health, Inc, Burlingame, CA) when used in a real-world setting to treat essential tremor (ET), 90% (n=178) of those treated had at least a 50% reduction in tremor power after treating their most severe tremors. Across all sessions 57% of those
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Antibody–Oligonucleotide Conjugate Shows Target Engagement in Myotonic Dystrophy Type 1https://practicalneurology.com/news/antibodyoligonucleotide-conjugate-shows-target-engagement-in-myotonic-dystrophy-type/2485921/Treatment with delpacibart etedesiran (del-desiran [AOC 1001]; Avidity Biosciences, San Diego, CA), a monoclonal antibody (mAb) oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing biomarkers in adults with myotonic dystrophy type 1 (DM1). These
- FDA Grants Breakthrough Therapy Designation to Delpacibart Zotadirsen for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy/2475932/Del-zota (delpacibart zotadirsen; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational therapy for the treatment of people with Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 ski
- Draft Guidelines for the Treatment of Infantile Epilepsy Syndromes: Comments Requestedhttps://practicalneurology.com/news/new-guidelines-proposed-for-treatment-of-infantile-epilepsy-syndromes-comments-requested/2475300/The American Epilepsy Society (AES) has released a comprehensive draft clinical practice guideline that provides evidence-based recommendations for the pharmacologic, surgical, and dietary treatment of epilepsy syndromes in infants aged <36 months. The guideline updates a previously published
- Ingrezza Treatment for Older Adults with Tardive Dyskinesia Safe and Effective Long-Term According to New Studyhttps://practicalneurology.com/news/ingrezza-treatment-for-older-adults-with-tardive-dyskinesia-demonstrates-long-term-safety-and-efficacy/2474394/According to results of a post hoc analysis of the KINECT-3 (NCT02274558) and KINECT-4 (NCT02405091) clinical studies published in the Journal of Clinical Psychiatry, older adults with tardive dyskinesia (TD) treated with once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Dieg
- Ingrezza Treatment for Tardive Dyskinesia Improved Functional, Social, Emotional, and Health-Related Quality of Life Measureshttps://practicalneurology.com/news/ingrezza-treatment-for-tardive-dyskinesia-improved-functional-social-emotional-and-health-related-quality-of-life-measures/2470633/Treatment with Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in functional, social, emotional, and health-related quality of life measures for people with tardive dyskinesia (TD). The findings of 3 separate analyses of clinical study and survey dat